×
About 87,265 results

Towards A Novel Multi-Epitopes Chimeric Vaccine for Simulating Strong Immune Responses ...
https://doi.org/10.3390/ijerph182010961
International Journal of Environmental Research and Publi... Ullah A, Ahmad S et. al.

Oct 24th, 2021 - Morganella morganii is one of the main etiological agents of hospital-acquired infections and no licensed vaccine is available against the pathogen. Herein, we designed a multi-epitope-based vaccine against M. morganii. Predicted proteins from fully sequenced genomes of the pathogen were subjected to a core sequences analysis, followed by the prioritization of non-redundant, host non-homologous...

Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in...
https://doi.org/10.1002/ppul.25740
Pediatric Pulmonology; Tural DA, Yalçın E et. al.

Oct 24th, 2021 - Inhaled recombinant human deoxyribonuclease (dornase alfa) and osmotic agents such as inhaled mannitol are used for improving the clearance of secretions of cystic fibrosis (CF) patients. We aimed to evaluate the long term clinical effects of adding dry powder inhaled (DPI) mannitol in subjects with CF who are taking daily dornase alfa. We conducted a retrospective case-control study on subject...

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase ...
https://doi.org/10.1007/s11523-021-00849-8 10.1007/s00277-013-1879-x 10.4103/jomfp.JOMFP_100_17 10.1182/asheducation-2012.1.402 10.1182/hematology.2020000093 10.1111/bjh.15412 10.1200/JCO.19.00172 10.1182/blood-2017-03-769620 10.1182/blood-2014-05-577189 10.1158/2326-6066.CIR-15-0059 10.18632/oncotarget.9256 10.1016/j.annonc.2020.04.010 10.1038/s41591-020-1044-8 10.1016/S1470-2045(17)30240-1 10.1016/S1470-2045(17)30900-2 10.1186/s40425-019-0746-2 10.1001/jamaoncol.2018.5428 10.1016/S1470-2045(16)30364-3 10.1001/jamaoncol.2018.0077 10.1056/NEJMoa2002788 10.1182/blood-2015-02-629600 10.1038/leu.2014.137 10.1158/1078-0432.CCR-10-2660 10.1200/JCO.2012.48.3685 10.2217/imt-2016-0002 10.1097/HS9.0000000000000401 10.3389/fimmu.2020.00577 10.1158/2326-6066.CIR-14-0118 10.1016/S1470-2045(13)70551-5 10.1158/1078-0432.CCR-17-1922 10.1158/1078-0432.CCR-19-2973 10.1038/bcj.2014.14 10.1200/JCO.2009.23.8329 10.1016/S1470-2045(09)70003-8 10.1182/BLOOD-2018-99-114438 10.1200/JCO.2013.54.8800 10.1080/10428194.2018.1474463 10.3109/10428194.2015.1110748 10.4049/jimmunol.0901619 10.3389/fonc.2018.00351 10.1182/bloodadvances.2019000784 10.1200/JCO.2015.65.9789 10.1200/JCO.18.00766
Targeted Oncology; Hawkes EA, Phillips T et. al.

Oct 24th, 2021 - Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis despite the availability of multiple treatment options. Preliminary evidence suggests that DLBCL may be responsive to programmed death ligand 1 (PD-L1)/programmed death 1 inhibitors. The JAVELIN DLBCL study was conducted to assess whether a combination of agents could augment and sustain the anti...

Role of Laser Interstitial Thermal Therapy in the Management of Primary and Metastatic ...
https://doi.org/10.1007/s11864-021-00912-6 10.1016/j.wneu.2021.02.044
Current Treatment Options in Oncology; Melnick K, Shin D et. al.

Oct 24th, 2021 - Laser interstitial thermal therapy (LITT) is a minimally invasive treatment option for brain tumors including glioblastoma, other primary central nervous system (CNS) neoplasms, metastases, and radiation necrosis. LITT employs a fiber optic coupled laser delivery probe stabilized via stereotaxis to deliver thermal energy that induces coagulative necrosis in tumors to achieve effective cytoreduc...

Non-alcoholic fatty liver disease: Current therapeutic options.
https://doi.org/10.1016/j.coph.2021.09.007
Current Opinion in Pharmacology; Majumdar A, Verbeek J et. al.

Oct 24th, 2021 - Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and has an estimated global prevalence of 25%. NAFLD is found in up to 80% of people with obesity and over 60% of patients with diabetes. Cardiovascular disease is the main cause of mortality, followed by extra-hepatic cancers and then liver-specific complications of cirrhosis and hepatocellular carcinoma...

Anti-TNFα vs thiopurines for the prevention of postoperative recurrence in Crohn's dise...
https://doi.org/10.1016/j.cgh.2021.10.021
Clinical Gastroenterology and Hepatology : the Official C... Beelen EMJ, Nieboer D et. al.

Oct 24th, 2021 - The superiority of anti-TNFα agents to thiopurines for the prevention of postoperative recurrence of Crohn's disease (CD) after ileocolonic resection remains controversial. In this meta-analysis of individual participant data (IPD-MA), the effect of both strategies was compared and assessed after risk stratification. After a systematic literature search, IPD were requested from randomized contr...

Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients...
https://doi.org/10.1016/j.clml.2021.09.009
Clinical Lymphoma, Myeloma & Leukemia; Zeidan AM, Jayade S et. al.

Oct 23rd, 2021 - Until recently, patients with MDSs could receive HMAs via intravenous (IV) or subcutaneous (SC) administration. An oral HMA was recently approved as an alternative to IV/SC administration. This study assessed the impact of IV/SC HMA on MDS patients, and their experience of, challenges with, and views about oral MDS treatment. We conducted an online cross-sectional survey among adult MDS patient...

Immunoglobulin A nephropathy in pediatrics: an up-to-date.
https://doi.org/10.1111/nep.13987
Nephrology (Carlton, Vic.); Paranhos RM, de Souza Figueiredo GA et. al.

Oct 23rd, 2021 - Immunoglobulin A nephropathy is the main cause of glomerulonephritis globally and an important etiology of end-stage renal disease in children. It has been considered an autoimmune disease that can lead to the production of autoantibodies against abnormal IgA1 and formation of immune complexes. These autoantibodies and immune complexes deposit in the glomeruli, resulting in renal injury. At the...

Host factors subverted by Mycobacterium tuberculosis: Potential targets for host direct...
https://doi.org/10.1080/08830185.2021.1990277
International Reviews of Immunology; Kalra R, Tiwari D et. al.

Oct 23rd, 2021 - Despite new approaches in the diagnosis and treatment of tuberculosis (TB), it continues to be a major health burden. Several immunotherapies that potentiate the immune response have come up as adjuncts to drug therapies against drug resistant TB strains; however, there needs to be an urgent appraisal of host specific drug targets for improving their clinical management and to curtail disease p...

The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520849
Drug Design, Development and Therapy; Ling Y, Hao ZY et. al.

Oct 23rd, 2021 - Pyridine-based ring systems are one of the most extensively used heterocycles in the field of drug design, primarily due to their profound effect on pharmacological activity, which has led to the discovery of numerous broad-spectrum therapeutic agents. In the US FDA database, there are 95 approved pharmaceuticals that stem from pyridine or dihydropyridine, including isoniazid and ethionamide (t...

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
https://clinicaltrials.gov/ct2/show/NCT01306019

Oct 22nd, 2021 - This is a Phase I/II non-randomized clinical trial of ex vivo hematopoietic stem cell (HSC) gene transfer treatment for X-linked severe combined immunodeficiency (XSCID, also known as SCID-X1) using a self-inactivating lentiviral vector incorporating additional features to improve safety and performance. The study will treat 13 patients with XSCID who are between 2 and 40 years of age and who h...

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04344795

Oct 22nd, 2021 - This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its MTD, safety, tolerability, pharmacokinetics (PD), pharmacodynamics (PK) and preliminary anti-tumor activity in subjects with advanced solid tumors. Subjects with all histologic ty...

Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening
https://clinicaltrials.gov/ct2/show/NCT05043077

Oct 22nd, 2021 - A non-inferiority, crossover, randomized controlled trial will be conducted for this purpose. Participants will be randomly assigned to receive either a) microdrops on their first and standard drops on their second screening examination a week later (M/S group), or b) standard drops first and microdrops a week later (S/M group). Microdrops (6.5 μL) will be instilled using a calibrated micropipe...

Second-line Treatment of Primary Autoimmune Hemolytic Anemia
https://clinicaltrials.gov/ct2/show/NCT05057468

Oct 22nd, 2021 - Auto-immune hemolytic anemia (AIHA) is a heterogeneous syndrome in adults. This disease is associated with significant morbidity-mortality. First-line treatment with prolonged corticosteroid is well identified but there is not enough data about cyclosporine treatment in case of resistance or dependence on steroids. the cyclosporine showed efficacy in many immune cytopenic diseases in the light ...

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
https://clinicaltrials.gov/ct2/show/NCT05035407

Oct 22nd, 2021 - Background: KK-LC-1 is a cancer germline (CG) antigen with expression restricted to germ cells (which lack MHC class I expression) in adults and epithelial cancers including lung, breast and gastric. This limited expression pattern makes it an ideal target for T Cell Receptor (TCR) gene therapy. TCR T cell therapy targeting CG antigens has been shown to induce objective responses without autoim...

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
https://clinicaltrials.gov/ct2/show/NCT05064319

Oct 22nd, 2021 - This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measur...

A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
https://clinicaltrials.gov/ct2/show/NCT05064878

Oct 22nd, 2021 - This is a 2-part multicenter trial. Part 1 is a 20-week randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study to examine the efficacy and safety of ZX008 as an adjunctive therapy (to existing concomitant treatment with antiepileptic treatments [AETs]) in children and adults with a CDD diagnosis and uncontrolled seizures. Part 1 of the study is 20 weeks in duration and w...

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT05088889

Oct 22nd, 2021 - This is a single arm, single institution study, which aims to evaluate the efficacy and safety of combination therapy with radiosurgery nivolumab and ipilimumab as a maintenance regimen following first line induction chemotherapy in patients with metastatic pancreatic cancer. Chemotherapy will be administrated for a minimum of 4 cycles. Patients who have not progressed on chemotherapy will rece...

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
https://clinicaltrials.gov/ct2/show/NCT05027945

Oct 22nd, 2021 - Background: In 2019, investigators at the National Institutes of Health defined a new disease syndrome named VEXAS: Vacuoles in bone marrow cells, E1 enzyme mutations, X-linked, Autoinflammatory, Somatic syndrome. This syndrome is characterized by inflammatory and hematologic features and is frequently accompanied by marrow dysplasia, progressive bone marrow failure, and in some cases, the deve...

Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism
https://clinicaltrials.gov/ct2/show/NCT05088798

Oct 22nd, 2021 - Congenital hyperinsulinism (CHI) is a clinically and genetically heterogeneous disorder that is the most common cause of permanent hypoglycemia in infants and children. More than 50% of the medically-unresponsive patients have focal disease. Which is characterized by a distinct region of Beta-cell hyperplasia in the pancreas, due to a somatic loss of a gene that regulates cell proliferation. Re...